SFL’s Managing Director and Head of UK Office to Speak at DIA Combination Products Workshop

SFL’s team to provide delegates with an understanding of the regulatory framework for drug/device combinations and drug/companion diagnostics in the EU

Online PR News – 06-September-2012 – Basel – SFL is pleased to announce that Shayesteh FĂĽrst-Ladani, Managing Director of the company and Amanda Maxwell, Head of the UK office of SFL, will be chairing sessions and speaking at the DIA’s upcoming Combination Products Workshop to be held on 18 September in Basel, Switzerland.

The workshop entitled “Anticipating the New Regulatory Landscape for Drug/Device Combinations and Companion Diagnostics: an Overview of the Current and Likely Future EU rules”, will provide delegates with a critical and timely insight into the changing regulatory landscape for these often complex and unique products.

The one-day workshop will focus on the differences between device and pharma regulations and highlight challenges facing manufacturers, who need to comply with elements of both regulatory structures. Furthermore, guidance to those who operate on the drug/device borderline where it is not immediately obvious which regulatory framework applies will be given. The workshop is particularly important given the latest discussions at European Commission on the revision of the European medical device and in-vitro diagnostics (IVD) legislations expected to be published end September 2012.

In her speech, Shayesteh will provide an overview of Commission discussions on the proposed revision of Medical Device Directives and current and changing regulatory framework for combination products in EU/US. She will also chair the session “Stakeholders’ roles in assessing combination products in the EU”, which will give an overview of future regulatory expectations among Notified Bodies, National Regulatory Agencies and the EMA, and of their experiences to date with combination products. It will also give an outline of legal criteria for determining the correct classification of borderline products.

Amanda will be chairing and speaking at the session “Regulatory requirements for companion diagnostics in the EU”, which will give attendees with an overview of the development and approval of Companion diagnostics. In her presentation, Amanda will provide an overview of Commission discussions on the proposed revision of the IVD Directive.

“Manufacturers of drug/device combination products and borderline products will be impacted by an increasingly strict regulatory environment in the EU,” commented Shayesteh. “It is essential that all stakeholders in this sector keep abreast of the changes and ensure that they remain legally compliant. This workshop will be valuable for attendees in providing information on how the new legislations are likely to change their day-to-day business.”